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Abstract
The metabolome is a system of small biomolecules (metabolites) and a direct result of
human bioculture. Consequently, metabolomics is well poised to impact anthropo-
logical and biomedical research for the foreseeable future. Overall, we provide a
perspective on the ethical, legal, and social implications (ELSI) of metabolomics,
which we argue are often more alarming than those of genomics. Given the cur-
rent mechanisms to fund research, ELSI beyond human DNA is stifled and in need
of considerable attention.
1 | INTRODUCTION
The metabolome, the totality of small molecules in a biological system
(Wishart et al., 2017), is arguably the most impactful biological sub-
system for health and wellness, given its central role in biochemistry
(Patti, Yanes, & Siuzdak, 2012). Although DNA forms a foundation for
biology, the action of molecular biology is happening above the
genome. Whether referring to the molecular interactions occurring
endogenously (from the genome and among the cells and organs) or
exogenously (from behavioral and environmental chemical exposures),
the metabolome is the highly dynamic molecular system that serves at
the nexus (Figure 1).
The metabolome is the molecular system most proximal to pheno-
type (the observable characteristics of an organism) and metabolomics
is exciting because it brings knowledge of mechanisms to health and
human biology. For example, translation of metabolomics knowledge
into treatments may be more straightforward than the human genome
because most drugs are themselves metabolite inspired, small mole-
cule agonists, or antagonists of signaling cascades and metabolism
(O0Hagan, Swainston, Handl, & Kell, 2015). Given the key role of small
molecules at the intersection of cultural, biological, and environmental
systems, metabolomics has a unique potential in a personalized medi-
cine framework; the metabolome is the biomolecularly realized mani-
festation of the social determinates of health. Metabolomics builds off
of a 100+ year legacy of characterizing biochemical pathways, prod-
ucts, and reaction intermediates (classic metabolites), laying the foun-
dation of the vast majority of biotechnological advances, including
nearly all current pharmaceuticals, pesticides, and vital nutrients
(German, Hammock, & Watkins, 2005). Using new tools, expanding
chemical libraries, and integrating with other forms of big data,
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metabolomics has entered a golden era of discovery, and well
deserves a central place in anthropological and biological research
programs, federal funding initiatives, and institutes.
Metabolomics initially focused on cellular metabolic pathways.
Driven by technological advances, a broader definition is gaining
acceptance, emphasizing all “omics”-scale research on small molecules
(<1,500 Da) (Wishart et al., 2017). Consequently, metabolomics
research, compared to other “omics” sciences, encompasses a broad
range of structurally diverse molecules from microbiome secondary
metabolites and food-derived molecules to xenobiotics (Wishart et al.,
2017). Thus, metabolomics can be considered an umbrella discipline
including a wide range of studies, such as lipidomics, exposomics,
fluxomics, which are deeply connected by scientific theory, protocols,
standards, methods, and frequently, ethical, legal, and social implica-
tions (ELSI).
2 | METABOLOMICS AND
ANTHROPOLOGY
The human metabolome is a direct result of human bioculture,
including human practices and the environment; thus, biological
anthropology is well situated to engage the metabolome. Yet,
metabolomics in anthropology has yet to solidify an identity.
Anthropological publications that directly refer to, or study, the
metabolome are most frequently associated with studies of the
human microbiome (Crittenden & Schnorr, 2017; Pafco et al., 2019;
Sankaranarayanan et al., 2015; Stumpf et al., 2013); however, the
metabolome and metabolites encompass much more of human biol-
ogy than that attributed to microbial ecologies. In fact, while metab-
olites are molecular, they are often nongenetic, revealing a form of
nongenetic molecular anthropology. Within archeology, an explicit
metabolomic characterization of ancient materials has begun
(Velsko et al., 2017). Yet, archeological approaches to metabolomics
have been around awhile; they may be concealed under a broader
objective of “residue analysis,” revealing remarkable discoveries of
human cultural practices through metabolites (e.g., Crown
et al., 2015).
3 | HEALTH, THE GENOME VERSUS THE
METABOLOME
The 100+ year legacy of metabolite science suggests that met-
abolomics is poised to have a greater claim to success in medicine
than genomics. The genome remains significant, to be sure, in that it
transcends the health of the individual and reflects the history and
potential future of our species. Moreover, genomic variation has dem-
onstrated a level of predictive power for some diseases and health
risks, although the predictive power of the genome alone may be lim-
ited for complex diseases (Roberts et al., 2012).
Most aspects of health and disease are complex, not directly
attributable to genes. Even considering emerging excitement and
concerns with CRISPR (Adli, 2018) and other gene editing technolo-
gies, these gene-based approaches will likely remain less relevant
than the vast array of metabolite-based interventions that impact our
life. One common misconception of genomics is that the combination
of the genome, transcriptome, and proteome determines function,
phenotype, and health; however, with respect to much biomolecular
activity, the system of gene expression is subordinate to the sub-
strates, products, and other modifiers involved in metabolic activity
(ter Kuile & Westerhoff, 2001). Thus, even with perfect data on gene
expression, this information still only conveys what might happen
during a metabolic process; in contrast, information from the
metabolome uncovers what is actually happening (Riekeberg & Pow-
ers, 2017).
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F IGURE 1 The metabolome serves as
the nexus of the interacting systems that
shape health
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4 | ELSI AND THE METABOLOME
Published research on the ELSI of metabolomics is essentially nonexis-
tent, although it may be mentioned in brief when referencing geno-
mics or related fields (see, e.g., Manasco, 2005). In two broad areas,
metabolomics has fewer ethical concerns: on average, (a) metabolomic
data are less ancestry informative; (b) metabolites are a more dynamic
system than genes and gene products, so our current metabolome
profile is less fixed than our germline profile, creating more opportuni-
ties for intervention. Also, some ethical issues in genomics have ana-
logues in metabolomics and can serve as foundations. But there are
other areas where differences are substantial, and genomic founda-
tions are unlikely to provide direct solutions to metabolomics ELSI.
We highlight these in the following.
4.1 | Privacy
The potential loss of personal privacy from the metabolome is greater
than most realize. The metabolome is shaped by where you live and
what you do, and consequently contains information on your environ-
ment and your practices; drugs, diet, and various environmental expo-
sures are traceable in the metabolome. Aspects of your behavior, your
practices, your biology, are not only impacting the metabolome in
your body, but the metabolites you leave behind. Your metabolome
can be characterized from your kitchen or bedroom, your keyboard at
home or work (Bouslimani et al., 2015; Bouslimani et al., 2016;McCall
et al., 2019 ; Petras et al., 2016). Indeed, metabolites left on phones
can be used to build a behavioral profile of the phones' owner, and
even to match them back together (Bouslimani et al., 2016). The
metabolome is therefore a molecular fingerprint different from DNA,
but equally impactful, and more so if the objective is to understand
human actions rather than human ancestry.
Health and the built environment are deeply tied (Perdue, Stone, &
Gostin, 2003). Metabolomics is poised to make significant contributions
to this area of research (Athersuch, 2016), but not without some major
concerns for privacy, misinterpretation, and misuse of results. Visualiza-
tions of the molecules of the built environment not only reveal an indi-
vidual's contact with their habitat, and the habitat's impact on the
individual, but also the diffusion of a chemical material culture within the
habitat, such as sanitizers, medication, personal care products, foods,
drinks, and their additives (McCall et al., 2019; Petras et al., 2016).
The chemical tracing of behavior, from the individual's behaviors to the
history of an item, has major implications for a range of sciences, and
certainly for ethics. One of the more profound examples is the presence
of cocaine in the built environment. It has been observed thatmost bank-
notes in circulation in theUnited States carry detectable levels of cocaine
(Zuo, Zhang, Wu, Rego, & Fritz, 2008). As proof of principle, one study
applied untargeted metabolomics to reveal the behavior in an apartment
(Petras et al., 2016), including associated belongings; unsurprisingly,
cocaine was detected although none was used by the occupants. Many
metabolites are “sticky” and can be found on objects months later
(Bouslimani et al., 2016). Detection of such molecules may not reflect a
person's current behavior, but rather their actions 6 months ago or the
actions of a previous owner of the object. Preventing misinterpretation
andoverinterpretation of such findingswill be amajor concern that inter-
sects privacy, exposomics, and health; policies to protect privacy and
human rights with the rise of metabolomics are needed. We should be
prepared for a world where molecular tools threaten personal privacy in
ways that are difficult to appreciate fully today.
4.2 | Policy
The United States Genetic Information Nondiscrimination Act (GINA) of
2008 is a federal law that provides some protections to those using
genetic tests or family history to learn about their health risks; health
insurers and employers are unable to request, require, or use this genetic
information to discriminate. The only metabolites specifically covered
under this law are those that directly predict genotypes, mutations, or
chromosomal changes. Any other metabolites are excluded from these
protections. For example, GINAdoes not cover current health conditions
and specifically excludes metabolites that are directly related to a
“manifested disease, disorder, or pathological condition that could rea-
sonably be detected”. This legal condition is problematic in met-
abolomics. Genetic mutations in one enzyme often affect the direct
product of that enzyme, but through cascade effects almost certainly
affect the downstream metabolic products, plus any pathways regulated
by downstream products, and the cells' compensatory mechanisms.
Moreover, the vast majority of health-associated metabolites are uni-
nformative of genetic variation. In other words, at this time, there are no
protections for most health- and behavior-associatedmetabolites. This is
a distinct privacy risk from other nongenetic health information, such as
weight and medicine use, because the metabolome is all encompassing,
not targeted, and there are no guidelines currently for delineating that
which is relevant and reasonable for insurers from that which needs fur-
ther protection fromdiscrimination.
4.3 | Intellectual property
Metabolomics-based biomarker tests are patentable, for example, the
U.S. company Metabolon holds over 30 U.S. patents on biomarkers
and biomarker identification methods, covering diseases such as ath-
erosclerosis, diabetes, amyotrophic lateral sclerosis, cancer, with addi-
tional applications to the study of drug mechanism of action, response
to drugs, and the link between gene expression and metabolite pro-
duction (Gall, Cobb, & Pappan, 2018; Hu et al., 2019; Kaddurah-
daouk & Kristal, 2006; Mitchell, Berger, Lawton, & Beecher, 2013;
Paige et al., 2014). Patenting specific metabolites for treatment pur-
poses may be more challenging. For metabolites present in nature and
already structurally described, only patents covering method of use or
production processes would be possible. Nevertheless, chemical mod-
ification may be straightforward and lead to derived patentable novel
chemical matter (Kartal, 2007), which raises questions on who owns a
trivially modified, but otherwise ubiquitous, metabolite.
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4.4 | Naïve use of race
Metabolomics is a new opportunity to conflate race and biology.
Although the complexities of race, identity, genetics, and health have
been the thesis of many publications, we know of no focused discus-
sions on the metabolome. We can expect a large pool of biochemist
with little exposure to such issues as their field, unlike genomics, has
largely been removed from the narrative. Yet through metabolomics,
racial/ethnic groups will be stereotyped and compartmentalized in
ways that speak more to the worldview of the researcher than the
elastic bioculture of people. In fact, attempts at identifying race-
specific metabolomic biomarkers have begun (Di Poto et al., 2018;
Shi, Yuan, Zhang, Feng, & Wang, 2019), and while these studies are
drafted to improve clinical practice for diverse people, the framing of
the problem is naïve to genetic and cultural diversity. Without ques-
tion, genetic ancestry and cultural practices impact biology and health,
and coassociate with culturally constructed racial groups, to various
degrees. Even so, the use of race or ethnicity as the primary focus of
research is rarely warranted (Berg et al., 2005). Although ethnicity or
racial identifications can have utility in study designs, especially with
regard to inclusion of diversity, culturally constructed racial groups are
merely proxies, often poor, for the underlying genomic and cultural/
environmental variables that directly impact health. To have precision,
the wiser approach is not to invent individual tests for races but indi-
vidual tests for individuals. So much of metabolomics is shaped by
practices, and the environment that the construction of race-specific
assays creates an unreliable rigidity of people.
4.5 | Disparities
The data available to science shape future science. Naturally, this
advocates for efforts to include diverse groups within science to avoid
reinforcing disparities. Yet, the impact of new and emerging sciences
is less understood and may expose participants to unpredicted risks.
These risks maybe more challenging to mitigate in socioeconomically
vulnerable populations compared with the general public. This is the
most universal protection dilemma impacting health disparities among
underrepresented groups. How do we give people the equal potential
for benefit, while mitigating potential risks, especially for the more
vulnerable? This is a challenging question for ELSI and metabolomics
that intersects and exacerbates all the above concerns of the ethical
handling of metabolomic data.
Intersecting race and disparities includes appeals to environmental
justice, as built environments in more impoverished areas are likely to
provide tangible evidence of disproportionate environmental toxins
relative the more affluent areas. Claims based on metabolomics will
need careful review, which also includes issues of social justice, pri-
vacy, and racial disparities.
4.6 | Funding and future
Support for ELSI research grew directly out of the National Institutes of
Health (NIH, 2019) Human Genome Project, and continues to be
overseen as an extramural research program in the National Human
Genome Research Institute (NHGRI). Over the past three decades, this
funding mechanism has become the primary source of U.S. extramural
funding for biomedical ethics. Not surprisingly, the majority of ELSI
research proposals focus on genome research and clinical applications of
genetic testing. Unfortunately, this emphasis is out of step with the
multi-omics revolution in the life sciences that has followed in the wake
of the human genome project. Armed with new insights and tools from
genomics, a wide array of biological fields are studying synergistic con-
nections among biological pathways and phenomena—and importantly,
focusing their efforts on the system of biomolecules above the genome
that are much more amenable to intervention, such as the metabolome.
NHGRI's consistent focus on human genetics has allowed ELSI
researchers to develop new strategies to understand genetics, evaluate
the benefits of genetic testing, and propose health policy that maxi-
mizes promise while minimizing harms (Burke et al., 2015). But a conse-
quence of this focus is a preoccupation with what is arguably the least
clinically actionable biomolecule, human DNA. It seems clear that we
need a broader ELSI program that is more responsive to, and inclusive
of, how biology works and how human biology is studied today. Given
that omics sciences are expanding rapidly, the need for broad institu-
tional recognition, identity, and investment in these sciences is critical.
The solution to improving support and awareness of ELSI and bio-
molecules is not simply broadening the scope of NHGRI (although that
would help), but also requires a commitment from other agencies, organi-
zations and institutions, including those within anthropology. Professional
societies, particularly those close to biological anthropology, can be doing
their part in creating professional awareness—that molecular anthropol-
ogy is not just about human DNA—and that the implications of molecules
are broader than ancestry, population history, and evolution. Many of
these issues would benefit from attention from other NIH institutes,
which often have minimal explicit investment in anything that resembling
ELSI, as well as outside NIH altogether, falling more within the purview
of other agencies (e.g., NSF) and foundations. The rise of these new
approaches requires, in our opinion, a much more sustained and coordi-
nated approach to engage the kind of issues we have anticipated here.
5 | CONCLUSIONS
If the past 100+ years of history is any indication, metabolites will lead
health detection and treatment discoveries for the foreseeable future,
and with the advent of metabolomic scale research, there is hope that
the momentum in drug discovery has a new catalyst. High-impact dis-
coveries like this, that are paradigm shifting in science and life chang-
ing in medicine and society, do not come often. They require deep
commitment, sacrifice, and often abundant failure and misdirection,
which will only be exacerbated if fear of research reduces participa-
tion by individuals, groups, and nations. At this time, there is a reason
for all to be concerned about the ELSI of metabolomics. To pave a
safer and productive path, there is a need for increased investment in
the ELSI above the genome, by institutes, by agencies, and by profes-
sional organizations.
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